E7386 + Lenvatinib + Doxorubicin + Paclitaxel
Phase 1/2Active 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Neoplasms
Conditions
Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms
Trial Timeline
Jul 11, 2019 → Mar 31, 2027
NCT ID
NCT04008797About E7386 + Lenvatinib + Doxorubicin + Paclitaxel
E7386 + Lenvatinib + Doxorubicin + Paclitaxel is a phase 1/2 stage product being developed by Eisai for Endometrial Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT04008797. Target conditions include Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04008797 | Phase 1/2 | Active |
Competing Products
20 competing products in Endometrial Neoplasms